Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Hongxing Liu, Sr., Min Xiong, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 218.

https://doi.org/10.1182/blood-2023-179086

Published: 2023

Journal Articles

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Xian Zhang, Lin Wang, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2023-185271

Published: 2023

Journal Articles

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Xian Zhang, Qinglong Wang, Ying Liu, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 6883.

https://doi.org/10.1182/blood-2023-185361

Published: 2023

Journal Articles

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Jianqiang Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 2369–2370.

https://doi.org/10.1182/blood-2022-158878

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

Journal Articles

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Xian Zhang, Junfang Yang, Jingjing Li, Yanze Shi, Yunchao Su, Ying Liu, Min Ba, Yan Wu, Wenqian Li, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2021-146425

Published: 2021

Journal Articles

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

Ying Liu, Weijing Li, Lin Wang, Min Ba, Qinglong Wang, Peihua Lu, Lihong Liu, Jianqiang Li

Blood (2021) 138 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2021-149384

Published: 2021

Journal Articles

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Junfang Yang, Xiao Yang, Ying Liu, Qinglong Wang, Hui Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 652.

https://doi.org/10.1182/blood-2021-147754

Published: 2021

Journal Articles

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Jingjing Li, Xinan Lu, Jianqiang Li, PhD, Xiangqun Li, Zhongwei Xu, Ziyu Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136897

Published: 2020

Journal Articles

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Liyuan Qiu, Xin-An Lu, Fei Wu, Jianqiang Li, PhD, Dandan Chen, Xiangqun Li, Ziyu Li, Jingjing Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-137299

Published: 2020

Journal Articles

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Junfang Yang, MD, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, PhD, Fei Wu, Jianqiang Li, Ph. D., Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu

Blood (2019) 134 (Supplement_1): 224.

https://doi.org/10.1182/blood-2019-125503

Published: 2019

Journal Articles

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Jianqiang Li, PhD, Jin-Yuan Ho, PhD, Lin Wang, Xing Niu, Min Ba, Qinglong Wang, Junfang Yang, MD, Xian Zhang, MD, Dandan Chen, Peihua Lu

Blood (2019) 134 (Supplement_1): 54.

https://doi.org/10.1182/blood-2019-125467

Published: 2019

Journal Articles

Evidence of Long-Lasting Anti-CD19 Activity of Engrafted CD19 Chimeric Antigen Receptor Modified T Cells in a Phase I Study Targeting Pediatrics with Acute Lymphoblastic Leukemia

Futian Ma, Jin-Yuan Ho, Huan Du, Fan Xuan, Xiaoli Wu, Ying Liu, Yizhuo Wang, Jianmin Luo, Jianqiang Li

Blood (2018) 132 (Supplement 1): 2701.

https://doi.org/10.1182/blood-2018-99-114346

Published: 2018

Journal Articles

A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia

Junfang Yang, MD, Jianqiang Li, Xian Zhang, PhD, Fanyong LV, Xiaoling Guo, Qinglong Wang, Lin Wang, Dandan Chen, Xiaosu Zhou, Jinhai Ren, MD, Peihua Lu

Blood (2018) 132 (Supplement 1): 277.

https://doi.org/10.1182/blood-2018-99-114415

Published: 2018

Journal Articles

Distinct Patterns of Early Hematopoietic Reconstitution in Patients Receiving Notch Expanded Non HLA-Matched Off-the-Shelf Cord Blood Derived Hematopoietic Stem and Progenitor Cells

Jianqiang Li, PhD MSc, Allen Jiang, Filippo Milano, MD PhD, Suzan Imren, MD, David Charles Keahi Oliver, BS, Joseph Blake, Colleen Delaney, MD MSc

Blood (2015) 126 (23): 379.

https://doi.org/10.1182/blood.V126.23.379.379

Published: 2015

Journal Articles

Notch-Expanded Murine Hematopoietic Progenitor Cells Can Induce Immune Tolerance in Mismatched Recipients

Fabiola V Merriam, PhD, Ian Nicoud, PhD, Filippo Milano, MD PhD, Jianqiang Li, PhD, Shelly Heimfeld, PhD, Colleen Delaney, MD

Blood (2014) 124 (21): 2430.

https://doi.org/10.1182/blood.V124.21.2430.2430

Published: 2014

Journal Articles

Real-Time Immunophenotyping of Peripheral Blood Early Post Myeloablative Cord Blood Transplant Can Identify Patients at Risk for Primary Graft Failure

Jianqiang Li, PhD, Filippo Milano, MD PhD, Joseph M Blake, David C. Oliver, Ian Nicoud, PhD, Shelly Heimfeld, PhD, Colleen Delaney, MD

Blood (2014) 124 (21): 3897.

https://doi.org/10.1182/blood.V124.21.3897.3897

Published: 2014

Journal Articles

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset

Christelle Harly, Yves Guillaume, Steven Nedellec, Cassie-Marie Peigné, Hannu Mönkkönen, Jukka Mönkkönen, Jianqiang Li, Jürgen Kuball, Erin J. Adams, Sonia Netzer, Julie Déchanet-Merville, Alexandra Léger, Thomas Herrmann, Richard Breathnach, Daniel Olive, Marc Bonneville, Emmanuel Scotet

Blood (2012) 120 (11): 2269–2279.

https://doi.org/10.1182/blood-2012-05-430470

Published: 2012

Includes: Supplemental data

Journal Articles

Detection and Characterization of Antigen-Driven CD8 + T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma

Ryotaro Nakamura, MD, Anna Israyelyan, MD, PhD, Corinna La Rosa, PhD, Weimin Tsai, BS, Teodora Kaltcheva, PhD, Tumul Srivastava, PhD, Jessica Lo, BS, Lia Aquino, Jianqiang Li, PhD, Young Kim, MD, Joycelynne Palmer, PhD, David Senitzer, PhD, John Zaia, MD, Stephen J. Forman, MD, Don J. Diamond, PhD

Blood (2011) 118 (21): 953.

https://doi.org/10.1182/blood.V118.21.953.953

Published: 2011

NARROW

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Evidence of Long-Lasting Anti-CD19 Activity of Engrafted CD19 Chimeric Antigen Receptor Modified T Cells in a Phase I Study Targeting Pediatrics with Acute Lymphoblastic Leukemia

A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia

Distinct Patterns of Early Hematopoietic Reconstitution in Patients Receiving Notch Expanded Non HLA-Matched Off-the-Shelf Cord Blood Derived Hematopoietic Stem and Progenitor Cells

Notch-Expanded Murine Hematopoietic Progenitor Cells Can Induce Immune Tolerance in Mismatched Recipients

Real-Time Immunophenotyping of Peripheral Blood Early Post Myeloablative Cord Blood Transplant Can Identify Patients at Risk for Primary Graft Failure

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset

Detection and Characterization of Antigen-Driven CD8 + T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only